AzTrials
AzTrials

Vitamin D DeficiencyPhase 2NCT03611049

Improving Functionality in Older People

A Phase 2 study testing High dose Vitamin D3 and Low dose Vitamin D3 in people with Vitamin D Deficiency, run by Texas Tech University Health Sciences Center at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The study will examine if overall functionality of older adults with Vitamin D insufficiency can be improved by optimal Vitamin D replacement over a period of approximately one year. A variety of outcome metrics will be examined including mental and physical parameters Read more about this study

Who is it for?
Ages 65 to 89 yearsHealthy volunteers can take part
Conditions the study is for
Vitamin D Deficiency
What is being tested?
High dose Vitamin D3 and Low dose Vitamin D3
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
14 participants
Where
1 siteUnited States
Study dates
1 Aug 2018to 19 Jul 2019
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 to 89 years
  • All sexes
  • Healthy volunteers accepted
  • Older adult

Who may be able to join

  • Community dwelling subject (adults) aged between 65 and 89 years of age
  • Subject should be ambulatory and living at home
  • Subject should be capable of self-care
  • Subject should be able to drive an automobile independently and without assistance
  • Subject should agree to home visitation by CRI coordinators to assess pill counts or willing to come to TTUHSC for such a visit
  • 25(OH) Vitamin D value < 30 ng/ml

Who cannot join

  • Participant unable or unwilling to have follow up for the duration of the study
  • Subject that cannot take a daily supplement
  • Subject unable to have MRI imaging
  • Subject on peritoneal or hemodialysis
  • Subject unwilling to have multiple blood draws
  • Subject with Sarcoidosis or diseases associated with hypercalcemia
Show all 15Show fewer
  • Subject currently taking supplements containing Vitamin D
  • Subject with prior cerebrovascular disease or memory problems
  • Subject with prior myocardial infarction or atrial fibrillation or on anticoagulants
  • Subject on medications for memory or cognitive issues or mental ill-health
  • Subject with life expectancy less than 2 years
  • Subject receiving assistance for self-care
  • Subject cannot pass motor screening test for valid assessment of cognition
  • Subject on medications for Diabetes
  • Subject on medication for hypertension

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Texas Tech University Health Sciences Center

    Lubbock, Texas, 79430

Other trials in United States

About this study

Official title: Improving Cognition and Brain Imagery Through Optimal Vitamin D Supplementation in the Elderly

The study will examine if overall functionality of older adults with Vitamin D insufficiency can be improved by optimal Vitamin D replacement over a period of approximately one year. A variety of outcome metrics will be examined including mental and physical parameters

Read the detailed description

The decline in brain function with aging is costly. The maintenance of optimal brain health is a priority among the elderly. Complex modifiable factors impact brain function such as education level, ongoing use of cognitive skills such as mentoring and social interaction. In most instances, substantial time and effort will be required to improve brain function in the elderly. There is an urgent need for an option that will yield rapid results. Investigator(s) believe intensive Vitamin D replacement presents such a solution.

Emerging scientific information supports an important role for Vitamin D in brain health. Much of this data is based on the association that higher Vitamin D values are linked to better brain function. However, an association does not prove a cause and effect. To prove that Vitamin D values play a causal role in cognition carefully controlled studies are needed. Currently, there are very few controlled interventional studies in the elderly demonstrating that Vitamin D levels can improve brain function. The 25(OH) Vitamin D is the best indicator of Vitamin D status. The normal range for 25(OH) Vitamin D is usually between 30 and 100 ng/ml. Preliminary data indicates that 25(OH) Vitamin D values of greater than 40 ng/ml are needed to improve brain function. Prior Vitamin D studies have used varying replacement protocols and types of Vitamin D such that stable 25(OH) Vitamin D values in the high normal range have rarely been achieved.

Brain Impairment usually occurs gradually in dementia, giving the patient and the provider an option to slow or halt progression of cognitive deterioration. Disruption in the white matter (reflecting the nerve fibers that conduct electric impulses) of the brain as well as reduction in brain volumes are linked to dementia and increasing chances of disability. These white matter abnormalities and reduction in brain volumes are commonly present in the elderly and are closely linked to Vitamin D deficiency. Animal studies using Vitamin D support a benefit to cognition. There is a paucity of carefully controlled clinical trials involving humans using appropriate Vitamin D replacement protocols. However, a few preliminary studies do support a benefit to cognition in humans over a study period ranging from 1-15 months. The present proposal addresses this relative deficiency by conducting a double blind controlled study in the Vitamin D insufficient community dwelling elderly.

The hypothesis is that daily 5000 IU Vitamin D3 will regress or at least prevent progression of white matter abnormalities or shrinking of brain volumes. There are specific anatomical defects in the brain linked to Vitamin D deficiency. These deficits include impaired visual memory and executive (higher brain functions). Investigator(s) will assess brain function by tracking changes in a battery of computerized tests that have been proven reliable in assessing brain function. These changes in computerized testing of brain skills will be matched to changes in brain imaging over the course of the 1 year study. Brain imaging will be done using a 3-Tesla Magnetic Resonance Imaging scan (MRI).

Once the institutional review board approves this study, free living participants (> 65 yrs.) without prior brain disease or dysfunction will be recruited. The participants with Vitamin D insufficiency (25(OH) Vitamin D < 30 ng/ml) will be randomized into two groups. Both participant groups will be treated for 1 year with daily Vitamin D3 supplements. The standard of care group will get 800 IU daily whereas the active group will get 5000 IU daily. Cognitive tests, chemistry profile will be done at baseline and every 4 months for 1 year. The basic chemistry profile (blood work) includes kidney function and calcium levels which also provide safety monitoring. Based on published information, Vitamin D3 doses planned in this study are far below the doses required for toxicity. The brain MRI will be done at baseline, 4 and 12 months.

Additional strengths of this study include a multidisciplinary team with published expertise and experience in Vitamin D replacement, brain and memory function.

Being tested
High dose Vitamin D3, Low dose Vitamin D3
Medical subject headings
Vitamin D Deficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High dose Vitamin D3Dietary supplement

    High dose arm- 5000IU given daily

  • Low dose Vitamin D3Dietary supplement

    Low dose arm-800 IU given daily

Study groups in NCT03611049
Study groupRoleWhat they receive
Low dose Vitamin D interventionPlacebo comparatorintervention includes 800 IU Vitamin D3 replacement
Receives: Dietary Supplement: Low dose Vitamin D3
High dose Vitamin D interventionActive comparatorIntervention includes 5000 IU Vitamin D3 replacement
Receives: Dietary Supplement: High dose Vitamin D3

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Muscle Strength

    Muscle strength will be determined by hand grip

    Measured: 1 year

  2. Gait speed

    Gait speed will be determined by timed walking

    Measured: 1 year

  3. Hippocampal and brain volumes

    Using a 3 Tesla MRI scanner using FreeSurfer software. Brain volumes are estimated in cubic centimeters and hippocampal volumes are estimated in cubic millimeters

    Measured: 1 year

  4. Body composition and regional fat distribution

    Body composition will be determined by bioelectrical impedance. Regional fat distribution will be assessed by waist hip ratio. Obesity will be determined through body mass index and percent body fat estimation through bioelectrical impedance

    Measured: 1 year

  5. Cognition

    Using a battery of tests from Cambridge Cognition. Each test will be given an equal value and a composite cognitive score determined by summation

    Measured: 1 year

  6. Quality of Life questionnaire

    Quality of life will be determined by SF-36 Questionnaire by Rand

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2018
  2. Study start1 Aug 2018
  3. Primary completion19 Jul 2019
  4. Study completion19 Jul 2019

Why it stopped: Principal Investigator (Dr. Peiris) is retiring

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Two parallel interventions in subjects with vitamin D insufficiency. A low dose vitamin D replacement arm and a high dose vitamin D replacement arm
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
14 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03611049
Sponsor's protocol ID
L18-111
Status last verified
Jul 2019
First submitted
11 May 2018
Last updated
23 Jul 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing High dose Vitamin D3 and Low dose Vitamin D3 in people with Vitamin D Deficiency, run by Texas Tech University Health Sciences Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 23 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Principal Investigator (Dr. Peiris) is retiring). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Muscle Strength (time frame: 1 year). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in